Overview

Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)

Status:
Not yet recruiting
Trial end date:
2026-08-01
Target enrollment:
Participant gender:
Summary
This study is a prospective, open-label, phase II clinical study for patients with HR+/HER2- advanced breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Fudan University
Treatments:
Albumin-Bound Paclitaxel
Paclitaxel